Latest news for Global Foo (OTC:PEASF) Stock

Global Food and Ingredients Inc is a plant-based food and ingredients company, focused on pulses and specialty crops chain for peas, beans, lentils, chickpeas and other high protein specialty crops. The Company supplies premium plant-based high protein ingredients to customers around the world and distributes truckload and less-than truckload of bagged product directly to food processing companies, foodservice companies and institutional buyers (educational institutions, healthcare facilities, correctional facilities, etc.) in North America.

GLOBAL FOOD AND INGREDIT by Global Food and Ingredients Ltd.

Global Food and Ingredients Inc

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Equal-Weight and raises the price target from $176 to $178.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Advanced Micro Devices, Raises Price Target to $178

RBC Capital analyst Irene Nattel reiterates George Weston (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WN#TSX">WN</a>) with a Outperform and maintains C$230 price target.

Reiteration

TSX:WN

RBC Capital Reiterates Outperform on George Weston, Maintains C$230 Price Target

Morgan Stanley analyst Toni Kaplan maintains Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) with a Equal-Weight and raises the price target from $243 to $260.

VRSK

Morgan Stanley Maintains Equal-Weight on Verisk Analytics, Raises Price Target to $260

RBC Capital analyst Maurice Choy reiterates Gibson Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GEI#TSX">GEI</a>) with a Outperform and maintains C$27 price target.

TSX:GEI

RBC Capital Reiterates Outperform on Gibson Energy, Maintains C$27 Price Target

Susquehanna analyst Christopher Rolland maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Neutral and maintains $125 price target.

SWKS

Susquehanna Maintains Neutral on Skyworks Solutions, Maintains $125 Price Target

Susquehanna analyst Joseph Stauff maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Negative and maintains $33 price target.

Susquehanna Maintains Negative on Caesars Entertainment, Maintains $33 Price Target

Susquehanna analyst Bascome Majors maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Neutral and maintains $80 price target.

Susquehanna Maintains Neutral on Canadian Pacific Kansas, Maintains $80 Price Target

Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) and Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares are trading higher today after the release of results of the annual power market auction by <a target="_blank" href="https://www.pjm.com/-/media/markets-ops/rpm/rpm-auction-info/2025-2026/2025-2026-base-residual-auction-report.ashx" rel="noreferrer noopener">PJM</a> Interconnection, the largest U.S. electrical grid operator.
Yesterday, PJM Interconnection disclosed the results of its 2025-2026 capacity auction, with prices for power plants reaching $269.92 per megawatt-day, up from $28.92 per megawatt-day in the previous year&#8217;s auction.
The 2025/2026 RPM Base Residual Auction cleared 135,684 MW of capacity from non-energy efficiency resources for annual, summer, and winter periods, resulting in an 18.6% reserve margin.
Guggenheim analysts said the decision was &#8220;directionally positive&#8221; for utilities such as Constellation and Vistra, and would provide a boost to their assets powered by fossil fuel, reported Reuters.
The report cited Jon Gordon, director at Advanced Energy United, a trade body, who added, &#8220;With transmission planning improvements on the docket and further interconnection reforms urgently needed, these auction results should send a clear message that change can&#8217;t come too soon.&#8221;
As per the report, the price increase in PJM&#8217;s service area, including states like New Jersey, Illinois, and Virginia, will take effect in June 2025.
Also, yesterday, Vistra disclosed that the Nuclear Regulatory Commission has approved extending the Comanche Peak Nuclear Power Plant&#8217;s operation through 2053, adding <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n40050235/vistra-receives-approval-to-operate-comanche-peak-nuclear-plant-through-2053" rel="noreferrer noopener">20 years to its original license</a>.
Investors can gain exposure to VST via&nbsp;Virtus Reaves Utilities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTES#NYSE">UTES</a>) and Series Portfolios Trust Adaptiv Select ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADPV#NYSE">ADPV</a>) and to CEG via EA Series Trust Strive FAANG 2.0 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTWO#NYSE">FTWO</a>).
Price Action: CEG shares are up 10.9% at $187.01 and VST rose by 14.3% at $78.83 at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Midjourney

Earnings

Equities

Large Cap

Movers

Media

ADPV

FTWO

UTES

Why Vistra and Constellation Energy Shares Are Jumping Today

Susquehanna analyst Christopher Rolland maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Positive and maintains $200 price target.

Susquehanna Maintains Positive on Advanced Micro Devices, Maintains $200 Price Target

Benchmark analyst Mark Palmer reiterates Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and maintains $17 price target.

Benchmark Reiterates Buy on Hut 8, Maintains $17 Price Target

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibb#NASDAQ">IBB</a>) is a passively managed exchange traded fund launched on 02/05/2001.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 4, placing it in top 25%.
<h2>Index Details</h2>
The fund is sponsored by Blackrock. It has amassed assets over $7.92 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. IBB seeks to match the performance of the Nasdaq Biotechnology Index before fees and expenses.
The ICE Biotechnology Index contains securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceuticals.
<h2>Costs</h2>
Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.
Annual operating expenses for this ETF are 0.45%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 0.27%.
<h2>Sector Exposure and Top Holdings</h2>
While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund&#39;s holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Vertex Pharmaceuticals Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) accounts for about 9.31% of total assets, followed by Amgen Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amgn#NASDAQ">AMGN</a>) and Regeneron Pharmaceuticals Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>).
The top 10 holdings account for about 53.07% of total assets under management.
<h2>Performance and Risk</h2>
The ETF has gained about 8.95% and was up about 14.19% so far this year and in the past one year (as of 07/31/2024), respectively. IBB has traded between $112.41 and $148.26 during this last 52-week period.
The ETF has a beta of 0.74 and standard deviation of 22.11% for the trailing three-year period, making it a high risk choice in the space. With about 221 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
IShares Biotechnology ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IBB is an excellent option for investors seeking exposure to the Health Care ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well.
First Trust NYSE Arca Biotechnology ETF (ARCA:FBT) tracks NYSE Arca Biotechnology Index and the SPDR S&amp;P Biotech ETF (ARCA:XBI) tracks S&amp;P Biotechnology Select Industry Index. First Trust NYSE Arca Biotechnology ETF has $1.16 billion in assets, SPDR S&amp;P Biotech ETF has $7.77 billion. FBT has an expense ratio of 0.56% and XBI charges 0.35%.
<a href="https://www.zacks.com/stock/news/2312595/should-you-invest-in-the-ishares-biotechnology-etf-ibb?cid=CS-BENZ-FT-sector_etf-2312595">To read this article on Zacks.com click here.</a>

Biotech

Markets

Trading Ideas

ETFs

General

AMGN

First Trust NYSE Arca Biotechnology Index Fund

REGN

VRTX

Should You Invest in the iShares Biotechnology ETF?

IAC Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iac#NASDAQ">IAC</a>) is scheduled to release second-quarter 2024 results on Aug 6 after market close.
The company&#39;s earnings outperformed the Zacks Consensus Estimate twice in the preceding four quarters, met the estimate once and missed on the remaining occasion, the average surprise being negative 51.4%. In the last reported quarter, it reported a loss of 93 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.14 per share.
Let&#39;s see how things have shaped up for IAC this earnings season.
<h3>Factors Likely to Have Shaped the Quarterly Performance</h3>
Persistent weakness in the company&#39;s service business and decreasing membership subscription revenues in the ads and leads business are expected to have weighed on the Angi segment&#39;s sales. The consensus mark for the segment&#39;s revenues is pegged at $301.7 million, indicating a 19.6% dip from the year-ago reported number.
The reduction in marketing by affiliate partners, which caused fewer visitors to ad-supported search and content websites, is expected to have hurt the Search segment. The Zacks Consensus Estimate for the segment&#39;s revenues is pegged at $110.1 million, which implies a 37.8% decline from the year-ago reported number.
Also, the softness in Mosaic Group and Care.com businesses is likely to have dented the Emerging &amp; Other segment&#39;s revenues. The Zacks Consensus Estimate for the segment&#39;s revenues is pegged at $101.4 million, indicating a 31.4% drop from the year-ago reported number.
Nevertheless, IAC&#39;s Dotdash Meredith segment is likely to have performed well driven by its strategic partnership and licensing agreement with OpenAI. Also, the positive response to the company&#39;s D/Cipher intent-targeting advertising solution in the market is likely to aid its results.
However, the ongoing migration of audience and advertising spending from print to digital within the print business is likely to have partially offset the gains. The Zacks Consensus Estimate for Dotdash Meredith segment&#39;s revenues is pegged at $422 million, which indicates 1.9% growth from the year-ago reported number.
Amid this backdrop, the Zacks Consensus Estimate for the company&#39;s second-quarter total revenues is pegged at $948.9 million, which indicates a decrease of 14.6% from the year-ago quarter&#39;s reported figure. The consensus estimate for adjusted loss is pinned at 39 cents per share, indicating a 48.7% increase from the year-ago quarter&#39;s reported number.
<div class="chart_embed">
<h3>IAC Inc. Price and EPS Surprise</h3>
<img alt="IAC Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/fc/1722429421.png" style="height:278px; width:588px" title="" />
IAC Inc. price-eps-surprise | IAC Inc. Quote
</div>
<h3>Earnings Whispers</h3>
Our proven model does not predict an earnings beat for IAC this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: IAC has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 39 cents per share.
Zacks Rank: IAC presently carries a Zacks Rank #3 (Hold).
<h3>Stocks to Consider</h3>
Here are some companies, which according to our model, have the right combination of elements to beat on earnings this reporting cycle.
Emerson Electric Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/emr#NYSE">EMR</a>) has an Earnings ESP of +0.14% and a Zacks Rank of 2 at present.
The company is scheduled to release second-quarter results on Aug 7.&nbsp;
EMR&#39;s earnings have surpassed the Zacks Consensus Estimate thrice in the preceding four quarters while missing the mark once, the average surprise being 10.7%.
ITT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/itt#NYSE">ITT</a>) has an Earnings ESP of +1.03% and a Zacks Rank of 3 at present. The company is slated to release second-quarter results on Aug 1.
ITT&#39;s earnings have surpassed the Zacks Consensus Estimate thrice and matched once in the trailing four quarters, the average surprise being 6.5%.
Chart Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gtls#NYSE">GTLS</a>) has an Earnings ESP of +12.52% and a Zacks Rank of 3 at present.
The company is slated to release second-quarter results on Aug 2. Chart Industries&#39; earnings have surpassed the Zacks Consensus Estimate twice in the trailing four quarters and missed the mark twice.
<a href="https://www.zacks.com/stock/news/2313031/iac-gears-up-to-report-q2-earnings-here-s-what-to-expect?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2313031">To read this article on Zacks.com click here.</a>

GTLS

IAC Gears Up to Report Q2 Earnings: Here's What to Expect

Investors with a lot of money to spend have taken a bullish stance on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TGT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Target.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $164,505, and 6 are calls, for a total amount of $449,680.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $160.0 for Target over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Target options trades today is 1830.88 with a total volume of 1,854.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Target's big money trades within a strike price range of $120.0 to $160.0 over the last 30 days.
<h3>Target 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722448001_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/23/24</td>
<td>$3.1</td>
<td>$2.94</td>
<td>$2.94</td>
<td>$157.50</td>
<td>$149.9K</td>
<td>53</td>
<td style="text-align: right;">514</td>
</tr>
<tr>
<td>TGT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$10.15</td>
<td>$10.0</td>
<td>$10.15</td>
<td>$145.00</td>
<td>$89.3K</td>
<td>2.5K</td>
<td style="text-align: right;">114</td>
</tr>
<tr>
<td>TGT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$8.0</td>
<td>$7.85</td>
<td>$8.0</td>
<td>$150.00</td>
<td>$80.0K</td>
<td>2.7K</td>
<td style="text-align: right;">215</td>
</tr>
<tr>
<td>TGT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.6</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$120.00</td>
<td>$77.0K</td>
<td>486</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>TGT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$8.0</td>
<td>$7.95</td>
<td>$7.95</td>
<td>$150.00</td>
<td>$59.6K</td>
<td>1.8K</td>
<td style="text-align: right;">109</td>
</tr>
</tbody>
</table>

<h3>About Target</h3>
Target serves as the nation's sixth-largest retailer, with its strategy predicated on delivering a gratifying in-store shopping experience and a wide product assortment of trendy apparel, home goods, and household essentials at competitive prices. Target's upscale and stylish image began to carry national merit in the 1990s—a decade in which the brand saw its top line grow threefold to almost $30 billion—and has since cemented itself as a leading US retailer.Today, Target operates over 1,950 stores in the United States, generates over $100 billion in sales, and fulfills over 2 billion customer orders annually. The firm's vast physical footprint is typically concentrated in urban and suburban markets as the firm seeks to attract a more affluent consumer base.
Having examined the options trading patterns of Target, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Target's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,247,030, the TGT's price is up by 1.21%, now at $149.75. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>What The Experts Say On Target</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $156.0.
<ul>
<li>An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $156. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Target, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In TGT Options

Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares are trading higher Wednesday in sympathy with Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), which jumped after reporting <a href="https://www.benzinga.com/news/earnings/24/07/40060832/amd-skyrockets-over-9-lifting-along-with-ai-rival-nvidia-whats-going-on">strong financial results for the second quarter</a>.
What Happened With AMD: AMD reported second-quarter revenue of $5.835 billion, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $5.724 billion. The chipmaker reported adjusted earnings of 69 cents per share, beating analyst estimates of 68 cents per share.
"We delivered strong revenue and earnings growth in the&nbsp;second quarter&nbsp;driven by record Data Center segment revenue. Our AI business continued accelerating and we are well positioned to deliver strong revenue growth in the second half of the year led by demand for Instinct, EPYC and Ryzen processors," said&nbsp;Lisa Su, chair and CEO of AMD.
"The rapid advances in generative AI are driving demand for more compute in every market, creating significant growth opportunities as we deliver leadership AI solutions across our business."
AMD said it expects third-quarter revenue to be between $6.4 billion and $7 billion versus estimates of $6.61 billion. The company anticipates third-quarter gross margin of approximately 53.5%. AMD also said on its conference call that it expects GPU revenue to exceed $4.5 billion this year, up from its prior forecast of approximately $4 billion.&nbsp;
AMD shares were up approximately 9% at the time of writing.
See Also: <a href="https://www.benzinga.com/markets/asia/24/07/40068710/markets-on-edge-ahead-of-fed-announcement-oil-spikes-after-hamas-leaders-death-boj-hikes-rates-euroz">Markets On Edge Ahead Of Fed Announcement: Oil Spikes After Hamas Leader&#8217;s Death, BoJ Hikes Rates, Eurozone Inflation Rises, US Jobs Disappoint</a>
Why It Matters: Several semiconductor names are moving higher alongside AMD as investors and analysts become more optimistic about chip earnings.
Arm is scheduled to report financial results for its fiscal first quarter after the market close on Wednesday. Analysts are looking for earnings of 34 cents per share and revenue of $902.691 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Last quarter, Arm reported earnings of 36 cents per share and revenue of $928 million in its third quarter as a public company. 
&#8220;This growth was driven by record royalty revenue as Armv9 adoption continues, especially in smartphones, server, and automotive markets. Revenue from licensing was also very strong, driven by multiple high-value agreements and the increased demand for Arm&#8217;s power-efficient technology for AI from data centers to edge computing," Arm CEO&nbsp;Rene Haas said at the time.
It&#8217;s worth noting that HSBC analyst Frank Lee on Monday downgraded Arm from a Hold rating to a Reduce rating, just days ahead of earnings.
What Else: Some chip stocks may also be getting a lift after Reuters reported that the Biden administration plans to propose a new rule next month that would expand the United States&#8217; ability to stop foreign exports of semiconductor manufacturing equipment to Chinese chipmakers.
The report indicates that shipments from allies that export key chipmaking equipment, including Japan, the Netherlands and South Korea, will be excluded from the new rule, limiting its impact, according to sources familiar with the matter.
ARM Price Action: Arm shares were up 7.21% at $142.55 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Previews

What's Going On With Arm Holdings Stock Wednesday?

Blackbaud (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blkb#NASDAQ">BLKB</a>) reported second-quarter 2024 non-GAAP earnings per share of $1.08, which surpassed the Zacks Consensus Estimate by 3.9%. The bottom line increased 10.2% year over year.
Total revenues jumped 6% year over year to $287.3 million, driven by growth in recurring revenues. Revenues missed the Zacks Consensus Estimate by 0.5%.
Total recurring revenues (contributed 98% to total revenues) in the reported quarter amounted to $281.4 million, up 7.2% year over year. One-time services and other revenues (2% of total revenues) totaled $5.9 million, down 31.7%.
<div class="chart_embed">
<h3>Blackbaud, Inc. Price, Consensus and EPS Surprise</h3>
<img alt="Blackbaud, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/30/1722432424.png" style="height:265px; width:574px" title="" />
Blackbaud, Inc. price-consensus-eps-surprise-chart | Blackbaud, Inc. Quote
Non-GAAP organic revenues were up 6.7% on a reported basis and 6.6% on a constant-currency basis, year over year. Non-GAAP organic recurring revenues rose 7.2%. 
Margin Details 
Non-GAAP gross margin was 62.9% compared with 61.6% a year ago.
Total operating expenses declined 19.3% on a year-over-year basis to $120.5 million.
Non-GAAP operating margin jumped 260 basis points (bps) to 30%.
Non-GAAP adjusted EBITDA margin was 35.7%, up 290 bps year over year. 
Balance Sheet &amp; Cash Flow 
As of Jun 30, 2024, Blackbaud had total cash, cash equivalents and restricted cash of $831.1 million compared with $382.9 million as of Mar 31, 2024.
Total debt (including the current portion) as of Jun 30, 2024, was $1021.9 million compared with&nbsp; $1039.8 million as of Mar 31, 2024.
For the second quarter, cash provided by operating activities was $53.8 million compared with $53.2 million in the prior-year quarter.
Non-GAAP adjusted free cash flow was $36.4 million compared with $43.6 million in the year-ago quarter.
Blackbaud repurchased approximately 3 million shares in the first half of 2024, representing 5.5% of the common stock outstanding at the end of 2023.
In July 2024, Blackbaud&#39;s board of directors approved a replenished and expanded $800 million stock repurchase authorization. BLKB expects to buy back up to 10% of the common stock outstanding in 2024 to offset dilution from annual stock-based compensation.&nbsp; 
Outlook 
Blackbaud reiterated its 2024 financial guidance, factoring in a significant, one-time expense to expedite crucial security initiatives. These initiatives, designed to provide long-term benefits for customers, include enhancing cybersecurity talent (both employees and third-party resources) and upgrading systems and tools to improve identity and privilege access management, as well as data loss prevention. The company anticipates that this accelerated cybersecurity investment will not recur in 2025 and beyond.
BLKB now expects non-GAAP revenues between $1.164 billion and $1.194 billion.
The company continues to project non-GAAP adjusted EBITDA margin in the range of 32.5-33.5%.
Non-GAAP EPS is anticipated to be between $4.12 and $4.38.
Non-GAAP adjusted free cash flow for 2024 is forecasted to be in the range of $254-$274 million.
Non-GAAP annualized effective tax rate is the same as the prior estimation of approximately 24.5%.
Interest expense is now expected in the band of $52 million to $56 million, changed from earlier guidance of $48 million to $52 million.
Fully diluted shares are now anticipated to be 51.0 million to 52.0 million compared with the earlier guided range of 52-53 million.
Capital expenditures are expected to be in the range of $65 million to $75 million, which includes $60-$70 million of capitalized software and content development costs. This remains the same as the earlier outlook. 
Zacks Rank and Stocks to Consider 
Blackbaud currently carries a Zacks Rank #3 (Hold)
Some better-ranked stocks from the broader technology space are Badger Meter,Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmi#NYSE">BMI</a>), SAP SE (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sap#NYSE">SAP</a>) and NVIDIA Corporation. BMI presently sports a Zacks Rank #1 (Strong Buy), whereas NVDA &amp; SAP carry a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for Badger Meter&#39;s 2024 EPS has increased 4.37% in the past 60 days to $4.06. BMI&#39;s long-term earnings growth rate is 17.9%. The company recently reported results for second-quarter 2024, wherein EPS of $1.12 topped the Zacks Consensus Estimate by 14.3%. Quarterly net sales were $216.7 million, up 23% from $175.9 million in the year-ago quarter and surpassed the consensus mark by 7.86%.
Badger Meter&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, delivering an average surprise of 12.89%. BMI shares have risen 24.3% in the past year.
The Zacks Consensus Estimate for SAP&#39;s 2024 EPS has increased 4.2% in the past 60 days to $4.75. SAP&#39;s long-term earnings growth rate is 10.7%. The company recently reported results for second quarter of 2024 wherein non-IFRS earnings came in at &euro;1.10 ($1.18) per share, climbing 59% from the year-ago quarter&#39;s levels. The Zacks Consensus Estimate was pegged at $1.01.
Total revenues on a non-IFRS basis of &euro;8.288 billion ($8,921.3 million), rose 10% year over year both at nominal and constant currencies basis. The Zacks Consensus Estimate was pegged at $8,864.7 million.
SAP&#39;s earnings beat the Zacks Consensus Estimate in three of the last four quarters, delivering an average earnings surprise of 4.0%. Shares of SAP have gained 51.6% in the past year.
The Zacks Consensus Estimate for NVDA&#39;s 2024 EPS has increased 1.5% in the past 60 days to $2.69. NVDA&#39;s long-term earnings growth rate is 37.6%.
NVIDIA&#39;s earnings beat the Zacks Consensus Estimate in three of the last four quarters, delivering an average earnings surprise of 18.43%. Shares of NVDA have gained 123.0% in the past year.
<a href="https://www.zacks.com/stock/news/2313190/blackbaud-blkb-q2-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2313190">To read this article on Zacks.com click here.</a>
</div>
&nbsp;

Earnings Beats

Guidance

Tech

BLKB

Blackbaud Q2 Earnings Beat Estimates, Revenues Up Y/Y

Deep-pocketed investors have adopted a bearish approach towards American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for American Airlines Gr. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 11% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $1,132,212, and 3 are calls, amounting to $155,710.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $8.0 to $25.0 for American Airlines Gr over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in American Airlines Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to American Airlines Gr's substantial trades, within a strike price spectrum from $8.0 to $25.0 over the preceding 30 days.
<h3>American Airlines Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722447996_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.1</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$12.00</td>
<td>$441.5K</td>
<td>24.8K</td>
<td>2.1K</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$14.35</td>
<td>$14.25</td>
<td>$14.3</td>
<td>$25.00</td>
<td>$426.1K</td>
<td>2</td>
<td>298</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.4</td>
<td>$15.00</td>
<td>$124.9K</td>
<td>1.7K</td>
<td>286</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/09/24</td>
<td>$0.85</td>
<td>$0.78</td>
<td>$0.82</td>
<td>$10.00</td>
<td>$82.0K</td>
<td>579</td>
<td>1.0K</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.05</td>
<td>$2.03</td>
<td>$2.05</td>
<td>$12.00</td>
<td>$61.5K</td>
<td>24.8K</td>
<td>2.4K</td>
</tr>
</tbody>
</table>

<h3>About American Airlines Gr</h3>
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
<h3>Where Is American Airlines Gr Standing Right Now?</h3>
<ul>
<li>With a trading volume of 16,905,192, the price of AAL is down by -1.21%, reaching $10.63.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for American Airlines Gr</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $11.75.
<ul>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on American Airlines Gr with a target price of $10. </li>
<li>Reflecting concerns, an analyst from Bernstein lowers its rating to Market Perform with a new price target of $12.</li>
<li>An analyst from Evercore ISI Group persists with their In-Line rating on American Airlines Gr, maintaining a target price of $13. </li>
<li>Reflecting concerns, an analyst from Bernstein lowers its rating to Market Perform with a new price target of $12.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Airlines Gr, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at American Airlines Gr's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Alcoa.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 69%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $74,493, and 11 are calls, for a total amount of $493,032.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $35.0 for Alcoa over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Alcoa stands at 3107.25, with a total volume reaching 9,957.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alcoa, situated within the strike price corridor from $25.0 to $35.0, throughout the last 30 days.
<h3>Alcoa Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722447991_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.25</td>
<td>$2.24</td>
<td>$2.24</td>
<td>$35.00</td>
<td>$77.0K</td>
<td>2.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$7.95</td>
<td>$7.9</td>
<td>$7.9</td>
<td>$25.00</td>
<td>$61.6K</td>
<td>58</td>
<td>96</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$0.73</td>
<td>$0.6</td>
<td>$0.61</td>
<td>$35.00</td>
<td>$56.7K</td>
<td>11.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/09/24</td>
<td>$1.65</td>
<td>$1.55</td>
<td>$1.65</td>
<td>$32.00</td>
<td>$55.4K</td>
<td>812</td>
<td>497</td>
</tr>
<tr>
<td>AA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.65</td>
<td>$0.61</td>
<td>$0.62</td>
<td>$35.00</td>
<td>$48.5K</td>
<td>11.3K</td>
<td>2.4K</td>
</tr>
</tbody>
</table>

<h3>About Alcoa</h3>
Alcoa Corp is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and the manufacture of primary aluminum. It is a bauxite miner and alumina refiner by production volume, and its profits are closely tied to prevailing commodity prices along the aluminum supply chain. The company segments include Bauxite; Alumina and Aluminum. It generates maximum revenue from the Aluminum segment. Geographically, it derives a majority of its revenue from the United States.
Following our analysis of the options activities associated with Alcoa, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Alcoa</h3>
<ul>
<li>With a trading volume of 3,511,754, the price of AA is up by 3.08%, reaching $32.75.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Alcoa</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $44.666666666666664.
<ul>
<li>Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Alcoa with a target price of $43. </li>
<li>An analyst from B. Riley Securities persists with their Neutral rating on Alcoa, maintaining a target price of $43. </li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Alcoa with a target price of $48. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alcoa options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Alcoa's Latest Options Trends

Lake Street analyst Jaeson Schmidt maintains Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) with a Buy and raises the price target from $35 to $46.

Lake Street Maintains Buy on Benchmark Electronics, Raises Price Target to $46

Skyworks Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) reported mixed third-quarter <a href="https://www.benzinga.com/news/earnings/24/07/40052319/skyworks-solutions-posts-mixed-q3-results-the-details">financial results on Tuesday</a>.
Skyworks Solutions reported quarterly earnings of $1.21 per share which missed the analyst consensus estimate of $1.23 and is a 30.06% decrease from the same period last year.
Quarterly sales came in at $905.5 million which beat the analyst consensus estimate of $900.4 million and represents a 15.47% decrease in sales from the same period last year.
"Skyworks generated solid results and strong profitability consistent with our guidance," said Liam K. Griffin, CEO of Skyworks. "Exiting the June quarter, our mobile business is ramping up while our broad markets business continues to recover. Over the medium-to-long-term, we expect generative AI applications will migrate to the edge, including the smartphone, driving a meaningful replacement cycle and leading to higher levels of RF complexity."
Skyworks expects fourth-quarter revenue to be between $1 billion to $1.04 billion with non-GAAP diluted earnings per share of $1.52 at the mid-point of the revenue range, versus the estimate of $1.51. The company expects its mobile business to be up approximately 20% sequentially, as demand and supply patterns appear to be normalizing.
Skyworks shares fell 5.7% to trade at $110.95 on Wednesday.
These analysts made changes to their price targets on Skyworks following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58fe05b80bd9910001595370/harsh-kumar">Piper Sandler analyst Harsh Kumar</a> reiterated Skyworks with a Neutral rating, while raising the price target from $95 to $115.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59972d99803ad30001fc246d/kevin-cassidy">Rosenblatt analyst Kevin Cassidy</a> maintained the stock with a Buy and raised the price target from $120 to $130.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad935ab85e930001f97192/ruben-roy">Stifel analyst Ruben Roy</a> maintained Skyworks with a Buy and boosted the price target from $112 to $125.</li>
<li><a href="https://widgets.benzinga.com/analyst-stock-ratings/analyst/588f38af77f9dd00016a51b8/tristan-gerra">Baird analyst Tristan Gerra</a> maintained the stock with a Neutral and raised the price target from $90 to $108.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b96e16b85e930001592a0e/anthony-stoss">Craig-Hallum analyst Anthony Stoss </a>maintained Skyworks with a Buy and raised the price target from $125 to $140..</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02943eaaa00018d9399/vivek-arya">B of A Securities analyst Vivek Arya</a> maintained Skyworks with an Underperform rating and boosted the price target from $95 to $110.</li>
</ul>
Read More:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow&#8217;</a></li>
</ul>

Skyworks Solutions Analysts Boost Their Forecasts After Q3 Results

MacroGenics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).
In May, when the company released interim data from the trial, MacroGenics reported five deaths <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38768977/macrogenics-gets-downgraded-following-disappointing-prostate-cancer-trial-results-w" rel="noreferrer noopener">(fatal outcome) during the trial</a>.
After reviewing, MacroGenics agreed with the study&#8217;s Independent Data Monitoring Committee&#8217;s recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants who could have received additional doses.
Most of these remaining study participants had already received 8-12 cycles of vobra duo. Participants continue to be monitored for adverse events, disease progression and survival.
&#8220;We decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment. We expect to have the data necessary to determine next steps for the vobra duo program later this year and will provide further updates on an investor call following our ESMO presentation,&#8221; said Dr. Scott Koenig, president and CEO of MacroGenics.
The company expects to have the mature efficacy findings, including median rPFS, later in the second half of 2024 and plans to present the data at a subsequent medical conference.
The company also announced a poster (display) presentation of clinical data from the TAMARACK Phase 2 study of vobra duo at the upcoming European Society for Medical <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38098131/macrogenics-analyst-impressed-by-improved-safety-profile-from-prostate-cancer-candi" rel="noreferrer noopener">Oncology (ESMO) Congress 2024</a>.
The abstract was based on an April 12 data cutoff, and the poster will report additional data from a July 9 data cutoff, including safety, efficacy, and landmark 6-month radiographic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40050124/macrogenics-provides-vobramitamab-duocarmazine-update" rel="noreferrer noopener">progression-free survival (rPFS) data</a>.
MacroGenics completed enrollment in the TAMARACK study in the fourth quarter of 2023 and plans to present the study&#8217;s landmark primary endpoint, the 6-month rPFS rate, which represents the proportion of study participants who remain alive and progression-free at six months.
Concurrently, MacroGenics achieved $100 million in milestones from Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) related to the development progress of Zynyz (retifanlimabz), following an agreement on July 24. Zynyz is indicated in the U.S. for metastatic or recurrent <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40049720/macrogenics-announces-achievement-of-100-million-in-milestones-related-to-retifanlimab-collaborati" rel="noreferrer noopener">locally advanced Merkel cell carcinoma</a>.
Analyst Reactions:
<ul>
<li>B. Riley Securities downgraded Macrogenics from Buy to Neutral and lowered the price target from $18 to $5.</li>
<li>Guggenheim downgraded Macrogenics from Buy to Neutral.</li>
<li>Barclays maintained Macrogenics with an Overweight and lowered the price target from $9 to $8.</li>
</ul>
MGNX Price Action: MacroGenics stock is down 28.59% at $3.75 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/40071226/teva-beats-q2-estimates-raises-annual-outlook-on-strong-generic-austedo-sales" target="_blank" rel="noreferrer noopener">Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales</a>.</li>
</ul>
Photo: Shutterstock

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Global Foo

News

Latest news for Global Foo (OTC:PEASF) Stock